Processa Pharmaceuticals (PCSA) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

PCSA Stock Forecast


Processa Pharmaceuticals stock forecast is as follows: an average price target of $9.00 (represents a 710.81% upside from PCSA’s last price of $1.11) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

PCSA Price Target


The average price target for Processa Pharmaceuticals (PCSA) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential 710.81% upside from PCSA's last price of $1.11.

PCSA Analyst Ratings


Buy

According to 3 Wall Street analysts, Processa Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PCSA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Processa Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 19, 2022-Maxim Group$9.00$3.18182.62%710.81%
Row per page
Go to

The latest Processa Pharmaceuticals stock forecast, released on Apr 19, 2022 by Maxim Group company, set a price target of $9.00, which represents a 182.62% increase from the stock price at the time of the forecast ($3.18), and a 710.81% increase from PCSA last price ($1.11).

Processa Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.11$1.11$1.11
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Processa Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Processa Pharmaceuticals's last price of $1.11. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 03, 2024H.C. WainwrightBuyBuyHold
Jan 12, 2023Maxim GroupBuyBuyHold
Aug 03, 2021Oppenheimer-OutperformInitialise
Row per page
Go to

Processa Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 03, 2024. The company gave PCSA a "Buy" rating, the same as its previous rate.

Processa Pharmaceuticals Financial Forecast


Processa Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Processa Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PCSA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Processa Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict PCSA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Processa Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Processa Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-1.57M$-1.54M$-1.80M$-2.16M$-2.49M$-3.28M$-3.01M
High Forecast$-1.57M$-1.54M$-1.80M$-2.16M$-2.49M$-3.28M$-3.01M
Low Forecast$-1.57M$-1.54M$-1.80M$-2.16M$-2.49M$-3.28M$-3.01M
Surprise %-------

Processa Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PCSA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Processa Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Processa Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PCSA last annual SG&A of $NaN (undefined).

Processa Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.48$-0.47$-0.55$-0.66$-0.76$-1.00$-1.01
High Forecast$-0.48$-0.47$-0.55$-0.66$-0.76$-1.00$-1.01
Low Forecast$-0.48$-0.47$-0.55$-0.66$-0.76$-1.00$-1.01
Surprise %-------

According to undefined Wall Street analysts, Processa Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PCSA previous annual EPS of $NaN (undefined).

Processa Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
AKTXAkari Therapeutics$2.43$12.00K493727.16%-
PMVPPMV Pharmaceuticals$1.64$24.751409.15%Buy
PCSAProcessa Pharmaceuticals$1.11$9.00710.81%Buy
ANTXAN2 Therapeutics$1.08$8.75710.19%Buy
FENCFennec Pharmaceuticals$4.65$15.75238.71%Buy
ANEBAnebulo Pharmaceuticals$1.89$6.00217.46%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
CELCCelcuity$15.36$31.50105.08%Buy
IKTInhibikase Therapeutics$2.61$5.0091.57%Buy
SABSSAB Biotherapeutics$4.04$5.6740.35%Buy
THRDThird Harmonic Bio$12.11$16.1533.36%Buy
ELVNEnliven Therapeutics$27.65$35.5028.39%Buy

PCSA Forecast FAQ


Yes, according to 3 Wall Street analysts, Processa Pharmaceuticals (PCSA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of PCSA's total ratings.

Processa Pharmaceuticals (PCSA) average price target is $9 with a range of $9 to $9, implying a 710.81% from its last price of $1.11. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for PCSA stock, the company can go up by 710.81% (from the last price of $1.11 to the average price target of $9), up by 710.81% based on the highest stock price target, and up by 710.81% based on the lowest stock price target.

PCSA's average twelve months analyst stock price target of $9 supports the claim that Processa Pharmaceuticals can reach $2 in the near future.

Processa Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-8.779M (high $-8.779M, low $-8.779M), average SG&A $0 (high $0, low $0), and average EPS is $-2.77 (high $-2.77, low $-2.77). PCSA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-7.076M (high $-7.076M, low $-7.076M), average SG&A $0 (high $0, low $0), and average EPS is $-2.16 (high $-2.16, low $-2.16).